| Literature DB >> 32533050 |
Han-Yu Deng1, Jie Zhou1, Ru-Lan Wang1, Rui Jiang1, Xiao-Ming Qiu1, Da-Xing Zhu1, Xiao-Jun Tang1, Qinghua Zhou2.
Abstract
Whether age has any impact on the risk of lymph node (LN) metastasis in patients with early-stage non-small cell lung cancer (NSCLC) remains controversial. Therefore, we aimed to objectively compare the risk of LN metastasis between elderly and young patients so as to justify for age-different extent of surgical resection for treating these patients. We retrospectively collected clinical data of patients undergoing lobectomy or segmentectomy with systematic hilar and mediastinal LN dissection for clinical stage IA peripheral NSCLC from January 2015 to December 2018. Both multivariate logistic regression analysis and propensity score-matched (PSM) analysis were applied to compare the risk of LN metastasis between elderly (>65 years old) and young (≤65 years old) patients. We finally included a total of 590 patients for analysis (142 elderly patients and 448 young patients). In the analysis of unmatched cohorts, young patients tended to have higher rates of hilar/intrapulmonary LN (13.4% VS 9.2%) and mediastinal LN metastasis (10.5% VS 6.3%) than elderly patients. In the multivariate analysis, age was found to be an independent predictor of both hilar/intrapulmonary (Odds ratio(OR) = 2.065, 95%confidence interval(CI): 1.049-4.064, P = 0.036) and mediastinal (OR = 2.400, 95%CI: 1.083-5.316, P = 0.031) LN metastasis. Moreover, in the analysis of well-matched cohorts generated by PSM analysis, young patients had significantly higher rates of hilar/intrapulmonary (18.8% VS 9.4%, P = 0.039) and mediastinal LN metastasis (17.1% VS 6.0%, P = 0.008) than elderly patients. Therefore, age remains to be an independent predictor of LN metastasis in early-stage NSCLC and age-different extent of surgical resection may be justified for these patients.Entities:
Mesh:
Year: 2020 PMID: 32533050 PMCID: PMC7293256 DOI: 10.1038/s41598-020-66509-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of these clinical T1N0M0 peripheral non-small cell lung cancer patients stratified by age.
| Characteristics | Total (N = 590) | Unmatched cohort | Matched cohort | ||||
|---|---|---|---|---|---|---|---|
| Young group(≤65 years old, N = 448) | Elderly group (>65 years old, N = 142) | P value | Young group(≤65 years old, N = 117) | Elderly group (>65 years old, N = 117) | P value | ||
| Age (Mean ± SD,years) | 58.1 ± 10.9 | 54.1 ± 9.0 | 71.1 ± 4.6 | <0.001 | 54.6 ± 8.3 | 71.1 ± 4.6 | <0.001 |
| Gender | 0.005 | 0.695 | |||||
| Male | 256(43.3%) | 180(40.2%) | 76(41.7%) | 56(47.9%) | 59(50.4%) | ||
| Female | 334(56.6%) | 268(59.8%) | 66(46.5%) | 61(52.1%) | 58(49.6%) | ||
| Tumor consistency | 0.009 | 0.617 | |||||
| Pure ground glass | 85(14.4%) | 75(16.7%) | 10(7.0%) | 10(8.5%) | 10(8.5%) | ||
| Part-solid | 114(19.3%) | 80(17.9%) | 34(23.9%) | 21(17.9%) | 27(23.1%) | ||
| Pure solid | 391(66.3%) | 293(65.40%) | 98(69.0%) | 86(73.5%) | 80(68.4%) | ||
| Histology | 0.008 | 0.729 | |||||
| Adenocarcinoma | 528(89.5%) | 409(91.3%) | 119(83.8%) | 98(83.8%) | 98(83.8%) | ||
| Lepidic group* | 191(32.4%) | 150(33.5%) | 41(28.9%) | 31(26.5%) | 35(29.9%) | ||
| Acinar predominant IA | 193(32.7%) | 147(32.8%) | 46(32.4%) | 37(31.6%) | 35(29.9%) | ||
| Papillary predominant IA | 22(3.7%) | 15(3.3%) | 7(4.9%) | 4(3.4%) | 6(5.1%) | ||
| Micropapillary predominant IA | 87(14.7%) | 73(16.3%) | 14(9.9%) | 21(17.9%) | 12(10.3%) | ||
| Solid predominant IA | 35(5.9%) | 24(5.4%) | 11(7.7%) | 5(4.3%) | 10(8.5%) | ||
| Squamous cell carcinoma | 47(8.0%) | 27(6.0%) | 20(14.1%) | 14(12.0%) | 16(13.7%) | ||
| Others | 15(2.5%) | 12(2.7%) | 3(2.1%) | 5(4.3%) | 3(2.6%) | ||
| Tumor location | 0.305 | 0.985 | |||||
| Right upper lobe | 220(37.3%) | 162(36.2%) | 58(40.8%) | 45(38.5%) | 46(39.3%) | ||
| Right middle lobe | 48(8.1%) | 37(8.3%) | 11(7.7%) | 10(8.5%) | 8(6.8%) | ||
| Right lower lobe | 84(14.2%) | 66(14.7%) | 18(12.7%) | 16(13.7%) | 15(12.8%) | ||
| Left upper lobe | 156(26.4%) | 126(28.1%) | 30(21.1%) | 27(23.1%) | 27(23.1%) | ||
| Left lower lobe | 82(13.9%) | 57(12.7%) | 25(17.6%) | 19(16.2%) | 21(17.9) | ||
| Tumor size (Mean ± SD, cm) | 1.90 ± 0.67 | 1.85 ± 0.69 | 2.04 ± 0.59 | 0.002 | 2.02 ± 0.64 | 2.00 ± 0.59 | 0.842 |
| Tumor differentiation | 0.031 | 0.614 | |||||
| G1 | 131(22.2%) | 100(22.3%) | 31(21.8%) | 21(17.9%) | 27(23.1%) | ||
| G2 | 292(49.5%) | 233(52.0%) | 59(41.5%) | 51(43.6%) | 49(41.9%) | ||
| G3 | 167(28.3%) | 115(25.7%) | 52(36.6%) | 45(38.5%) | 41(38.5%) | ||
| pT stage | 0.010 | 0.244 | |||||
| Tis | 15(2.5%) | 14(3.1%) | 1(0.7%) | 5(4.3%) | 1(0.9%) | ||
| T1mi | 42(7.1%) | 37(8.3%) | 5(3.5%) | 6(5.1%) | 4(3.4%) | ||
| T1a | 56(9.5%) | 50(11.2%) | 6(4.2%) | 7(6.0%) | 6(5.1%) | ||
| T1b | 163(27.6%) | 115(25.7%) | 48(33.8%) | 27(23.1%) | 41(35.0%) | ||
| T1c | 152(25.8%) | 110(24.6%) | 42(29.6%) | 33(28.2%) | 31(26.5%) | ||
| T2a | 162(27.5%) | 122(27.2%) | 40(28.2%) | 39(33.3%) | 34(29.1%) | ||
| pN stage | 0.285 | 0.025 | |||||
| N0 | 507(85.9%) | 382(85.3%) | 125(88.0%) | 90(76.9%) | 104(88.9%) | ||
| N1 | 27(4.6%) | 19(4.2%) | 8(5.6%) | 7(6.0%) | 6(5.1%) | ||
| N2 | 56(9.5%) | 47(10.5%) | 9(6.3%) | 20(17.1%) | 7(6.0%) | ||
| Visceral pleural invasion | 0.827 | 0.480 | |||||
| Yes | 162(27.5%) | 122(27.2%) | 40(28.2%) | 39(33.3%) | 34(29.1%) | ||
| No | 428(72.5%) | 326(72.8%) | 102(71.8%) | 78(66.7%) | 83(70.9%) | ||
| Total dissected LN number (Mean ± SD) | 12.3 ± 5.8 | 12.1 ± 5.7 | 12.9 ± 5.9 | 0.146 | 12.7 ± 5.7 | 12.5 ± 5.8 | 0.776 |
| Total dissected intrapulmonary/hilar LN number (Mean ± SD) | 4.1 ± 3.2 | 4.1 ± 3.1 | 4.0 ± 3.5 | 0.721 | 4.5 ± 3.3 | 3.9 ± 3.2 | 0.119 |
| Total dissected mediastinal LN number (Mean ± SD) | 8.2 ± 4.1 | 8.0 ± 4.1 | 8.9 ± 4.3 | 0.022 | 8.2 ± 3.9 | 8.6 ± 4.3 | 0.399 |
| LN metastasis rate | 83(14.1%) | 66(14.7%) | 17(12.0%) | 0.410 | 27(23.1%) | 13(11.5%) | 0.015 |
| N1 LN metastasis rate | 72(12.4%) | 60(13.4%) | 13(9.2%) | 0.181 | 22(18.8%) | 11(9.4%) | 0.039 |
| N2 LN metastasis rate | 56(9.5%) | 47(10.5%) | 9(6.3%) | 0.141 | 20(17.1%) | 7(6.0%) | 0.008 |
Note: SD = standard deviation; invasive adenocarcinoma. *Lepidic group contains adenocarcinoma in situ, minimally invasive adenocarcinoma and lepidic predominant invasive adenocarcinoma.
Figure 1The median number of dissected lymph node and lymph node metastasis rate subgrouped by age: (A) N1 lymph node and (B) N2 lymph node.
Multivariate regression analysis for risk factors of lymph node metastasis among clinical stage IA (cT1N0M0) peripheral non-small cell lung cancer patients.
| Characteristics | Odds Ratio | 95% Confidence Interval | P value |
|---|---|---|---|
| LN metastasis | |||
| Age (young VS elderly) | 1.691 | 0.910–3.142 | 0.097 |
| Gender (male VS female) | 0.730 | 0.423–1.259 | 0.257 |
| Tumor consistency (pure solid VS part-solid/pure ground glass) | 4.505 | 1.713–11.850 | 0.002 |
| Histology (adenocarcinoma VS nonadenocarcinoma) | 0.764 | 0.372–1.564 | 0.463 |
| Tumor size (cm) | 1.603 | 1.007–2.551 | 0.047 |
| Tumor differentiation (G3 VS G1/G2) | 3.860 | 2.243–6.643 | <0.001 |
| Visceral pleural invasion (yes VS no) | 1.529 | 0.899–2.601 | 0.117 |
| N1 LN metastasis | |||
| Age (young VS elderly) | 2.065 | 1.049–4.064 | 0.036 |
| Gender (male VS female) | 0.770 | 0.435–1.362 | 0.369 |
| Tumor consistency (pure solid VS part-solid/pure ground glass) | 11.274 | 2.644–48.069 | 0.001 |
| Histology (adenocarcinoma VS nonadenocarcinoma) | 0.460 | 0.226–0.938 | 0.033 |
| Tumor size (cm) | 1.283 | 0.790–2.083 | 0.313 |
| Tumor differentiation (G3 VS G1/G2) | 2.779 | 1.587–4.867 | <0.001 |
| Visceral pleural invasion (yes VS no) | 1.615 | 0.923–2.825 | 0.093 |
| N2 LN metastasis | |||
| Age (young VS elderly) | 2.400 | 1.083–5.316 | 0.031 |
| Gender (male VS female) | 0.612 | 0.320–1.170 | 0.137 |
| Tumor consistency (pure solid VS part-solid/pure ground glass) | 3.108 | 1.033–9.349 | 0.044 |
| Histology (adenocarcinoma VS nonadenocarcinoma) | 1.422 | 0.555–3.640 | 0.463 |
| Tumor size (cm) | 1.516 | 0.867–2.652 | 0.145 |
| Tumor differentiation (G3 VS G1/G2) | 6.250 | 3.172–12.314 | <0.001 |
| Visceral pleural invasion (yes VS no) | 1.738 | 0.935–3.232 | 0.080 |
Note: LN = lymph node.